The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases

R Chowdhury, KK Yeoh, YM Tian, L Hillringhaus… - EMBO …, 2011 - embopress.org
R Chowdhury, KK Yeoh, YM Tian, L Hillringhaus, EA Bagg, NR Rose, IKH Leung, XS Li…
EMBO reports, 2011embopress.org
Mutations in isocitrate dehydrogenases (IDHs) have a gain‐of‐function effect leading to R
(−)‐2‐hydroxyglutarate (R‐2HG) accumulation. By using biochemical, structural and cellular
assays, we show that either or both R‐and S‐2HG inhibit 2‐oxoglutarate (2OG)‐dependent
oxygenases with varying potencies. Half‐maximal inhibitory concentration (IC50) values for
the R‐form of 2HG varied from approximately 25 μM for the histone N ε‐lysine demethylase
JMJD2A to more than 5 mM for the hypoxia‐inducible factor (HIF) prolyl hydroxylase. The …
Mutations in isocitrate dehydrogenases (IDHs) have a gain‐of‐function effect leading to R(−)‐2‐hydroxyglutarate (R‐2HG) accumulation. By using biochemical, structural and cellular assays, we show that either or both R‐ and S‐2HG inhibit 2‐oxoglutarate (2OG)‐dependent oxygenases with varying potencies. Half‐maximal inhibitory concentration (IC50) values for the R‐form of 2HG varied from approximately 25 μM for the histone Nε‐lysine demethylase JMJD2A to more than 5 mM for the hypoxia‐inducible factor (HIF) prolyl hydroxylase. The results indicate that candidate oncogenic pathways in IDH‐associated malignancy should include those that are regulated by other 2OG oxygenases than HIF hydroxylases, in particular those involving the regulation of histone methylation.
embopress.org